-
EP4175955
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4175955
| EP4175955 - QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 07.04.2023 Database last updated on 13.07.2024 | |
| Former | The international publication has been made Status updated on 07.01.2022 | Most recent event Tooltip | 11.05.2024 | Supplementary search report | published on 12.06.2024 [2024/24] | Applicant(s) | For all designated states vTv Therapeutics LLC 3980 Premier Drive, Suite 310 High Point, NC 27265 / US | [2023/19] | Inventor(s) | 01 /
GADDAM, Bapu Ellicott City, Maryland 21043 / US | [2023/19] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2023/19] | Application number, filing date | 20942443.1 | 31.07.2020 | [2023/19] | WO2020US44410 | Priority number, date | US202063045240P | 29.06.2020 Original published format: US 202063045240 P | [2023/19] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022005494 | Date: | 06.01.2022 | Language: | EN | [2022/01] | Type: | A1 Application with search report | No.: | EP4175955 | Date: | 10.05.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.01.2022 takes the place of the publication of the European patent application. | [2023/19] | Search report(s) | International search report - published on: | KR | 06.01.2022 | (Supplementary) European search report - dispatched on: | EP | 10.05.2024 | Classification | IPC: | C07D471/04, A61K31/519, A61P29/00 | [2023/19] | CPC: |
A61P1/00 (EP,CN);
C07D471/04 (EP,CN,KR,US);
A61K31/4738 (KR);
A61P1/02 (EP,CN);
A61P1/04 (EP,CN);
A61P1/12 (EP,CN);
A61P1/16 (EP,CN);
A61P11/00 (EP,CN,KR);
A61P11/02 (EP,CN);
A61P11/06 (EP,CN,KR);
A61P13/12 (EP,CN);
A61P17/00 (EP,CN);
A61P17/06 (EP,CN,KR);
A61P17/16 (EP,CN);
A61P19/02 (EP,CN,KR);
A61P19/10 (EP,CN);
A61P21/04 (EP,CN);
A61P25/00 (EP,CN);
A61P25/16 (EP,CN);
A61P25/24 (EP,CN);
A61P25/28 (EP,CN);
A61P27/02 (EP,CN);
A61P29/00 (EP,CN,KR);
A61P3/10 (EP,CN);
A61P31/06 (EP,CN);
A61P31/12 (CN);
A61P35/00 (CN);
A61P37/02 (CN);
A61P37/08 (CN);
A61P7/02 (EP,CN);
A61P7/06 (EP,CN);
A61P9/04 (EP,CN);
A61P9/10 (EP,CN);
Y02A50/30 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/19] | Title | German: | CHINOLINDERIVATE, PHARMAZEUTISCH UNBEDENKLICHE SALZE UND VERFAHREN ZUR VERWENDUNG DAVON | [2023/19] | English: | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | [2023/19] | French: | DÉRIVÉS DE QUINOLÉINE, SELS PHARMACEUTIQUEMENT ACCEPTABLES ET LEURS PROCÉDÉS D'UTILISATION | [2023/19] | Entry into regional phase | 28.12.2022 | National basic fee paid | 28.12.2022 | Search fee paid | 28.12.2022 | Designation fee(s) paid | 28.12.2022 | Examination fee paid | Examination procedure | 28.12.2022 | Examination requested [2023/19] | 11.08.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.12.2022 | Renewal fee patent year 03 | 27.07.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO9857936 (DARWIN DISCOVERY LTD [GB]); | [A]US2003105129 (MORTLOCK ANDREW AUSTEN [GB], et al); | [A]WO2009125809 (DAIICHI SANKYO CO LTD [JP], et al); | [X]US2010190808 (MJALLI ADNAN M M [US], et al); |